TY  - JOUR

T1  - A randomized open-label phase II study evaluating antitumor activity of the survivin antisense oligonucleotide LY2181308 (LY) in combination with docetaxel (DO) for second-line treatment of patients with non-small cell lung cancer (NSCLC) using change in tumor size (CTS).

JO  - Journal of Clinical Oncology

PY  - 2013/05/20

AU  - Talbot DC

AU  - Blackhall FH

AU  - Kowalski D

AU  - Ramlau R

AU  - Bepler G

AU  - Grossi F

AU  - Lerchenmuller CA

AU  - Pinder MC

AU  - Mezger J

AU  - Danson S

AU  - Callies S et al

ED  - 

DO  - DOI: 10.1200/jco.2013.31.15_suppl.8051

PB  - American Society of Clinical Oncology (ASCO)

VL  - 31

IS  - 15_suppl

SP  - 8051

EP  - 8051

Y2  - 2025/01/03

ER  -